NEW ORLEANS, LA--(Marketwire - Oct 21, 2011) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, Former Attorney General of Louisiana, Charles C. Foti, Jr., announce the commencement of a securities class action lawsuit filed in the U.S. District Court for the Eastern District of Missouri, against K-V Pharmaceutical Company ("K-V" or the "Company") (NYSE: [ KV-A ]) (NYSE: [ KV-B ]) and certain of the Company's officers. The action is brought on behalf of those purchasing the common stock of K-V between February 14, 2011 and April 4, 2011, inclusive (the "Class Period").

What You May Do
If you are a K-V Pharmaceutical shareholder and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, e-mail or call KSF Managing Partner, Lewis Kahn ([ lewis.kahn@ksfcounsel.com ]), toll free, 877-515-1850, or via cell phone any time at 504-301-7900. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by December 19, 2011.

Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. KSF also encourages anyone with information regarding K-V Pharmaceutical's conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.

About the Lawsuit
K-V Pharmaceutical and certain of its officers and directors are charged with making a series of materially false and misleading statements related to the Company's business and operations in violation of the Securities Exchange Act of 1934. The complaint alleges that that during the brief Class Period, the Company issued false and misleading statements concerning "Makena," a drug compound sold by K-V. The complaint further alleges that defendants failed to reveal to investors that the exorbitant, $1,500 list price K-V was charging for this drug would limit its availability by making it unaffordable to many of its potential customers. According to the complaint, it was only after the company sold $200 million worth of senior secured notes, that investors began to learn the truth about K-V Pharmaceutical. Thus, beginning on March 17, 2011, two U.S. Senators raised questions about the Company, then on March 30, 2011, the U.S. Food and Drug Administration issued a statement that the FDA would not take enforcement action against K-V's competitors for distributing the generic version of Makena. Finally, on April 1, 2011, K-V disclosed that it would be forced to reduce the price of its Makena treatments by approximately 55% per injection. These belated disclosures caused the price of K-V Pharmaceutical's shares to decline precipitously, causing shareholders material damage and losses.

About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities class action and shareholder derivative litigation with offices in New York and Louisiana. KSF's lawyers have significant experience litigating complex securities class actions nationwide on behalf of both institutional and individual shareholders. To learn more about KSF, you may visit [ www.ksfcounsel.com ].